Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)
Significant reductions in relevant inflammatory biomarkers were observed in the LAVOLTA I and LAVOLTA II studies.
Authors
- Jonathan I. Silverberg (ORCID: https://orcid.org/0000-0003-3686-7805)
- Jonathan Corren (ORCID: https://orcid.org/0000-0001-5951-3239)
- Chitra R Natalie
- Stanley J. Szefler (ORCID: https://orcid.org/0000-0002-6911-3199)
- Ralph Zitnik
- Zhe Sun (ORCID: https://orcid.org/0000-0002-4633-7675)
- Kimberly Siu
- Andrew Blauvelt (ORCID: https://orcid.org/0000-0002-2633-985X)
- Angela J. Okragly (ORCID: https://orcid.org/0000-0002-1041-8000)
Institutions
- University of California, Los Angeles (US)
- Eli Lilly (United States) (US)
- George Washington University (US)
- Children's Hospital Colorado (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Immunotherapy
- Published
- 2024-12-15
- DOI
- https://doi.org/10.1080/1750743x.2024.2439777
- Citations
- 6
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.96
Funders
- Eli Lilly and Company